Literature DB >> 24379001

Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.

Casper N Bang1, Peter M Okin, Lars Køber, Kristian Wachtell, Alice Bendix Gottlieb, Richard B Devereux.   

Abstract

BACKGROUND: Inflammation contributes to the pathogenesis of psoriasis as well as atrial fibrillation. The impact of psoriasis and its association with new-onset atrial fibrillation was assessed in hypertensive patients with left ventricular hypertrophy (LVH).
METHODS: The predictive value of baseline or incident psoriasis for new-onset atrial fibrillation was evaluated in 7099 hypertensive patients with electrocardiographic LVH with no history of atrial fibrillation or other cardiovascular disease, in sinus rhythm on their baseline electrocardiogram.
RESULTS: A total of 154 patients (2.2%) had or developed psoriasis and new-onset atrial fibrillation occurred in 506 patients (7.1%) during a mean follow-up of 4.7 ± 1.1 years. At baseline, the psoriasis patients were younger (65 ± 7 vs. 67 ± 7 years) and had less left ventricle hypertrophy by ECG Sokolow-Lyon voltage (27.6 ± 9.7 vs. 30.1 ± 10.4 mm); higher hemoglobin (6.3 ± 2.2 vs. 6.0 ± 2.7 mmol/l) and prevalence of diabetes (20.6 vs. 12.8%, P ≤ 0.004) than patients without psoriasis. In multivariable Cox analysis, adjusting for age, sex, hemoglobin, diabetes, time-varying SBP, heart rate, study treatment and Sokolow-Lyon hypertrophy, psoriasis, treated as a time-varying covariate, was associated with a two-fold higher risk of new-onset atrial fibrillation [hazard ratio: 1.97 (95% confidence interval (CI): 1.18-3.30), P=0.01]. Propensity-matched analysis yielded similar results (odds ratio: 3.49, 95% CI 1.24-9.81, P=0.018).
CONCLUSION: Psoriasis has a similar prevalence in hypertensive patients as in the general population. Psoriasis independently predicted new-onset atrial fibrillation despite lower age and electrocardiographic LVH in psoriasis patients than in patients without psoriasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24379001     DOI: 10.1097/HJH.0000000000000078

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.

Authors:  Moa P Lee; Rishi J Desai; Yinzhu Jin; Gregory Brill; Alexis Ogdie; Seoyoung C Kim
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

2.  Risk of Atrial Fibrillation or Flutter Associated with Periodontitis: A Nationwide, Population-Based, Cohort Study.

Authors:  Der-Yuan Chen; Ching-Heng Lin; Yi-Ming Chen; Hsin-Hua Chen
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

3.  Atrial electromechanical delay is impaired in patients with psoriasis.

Authors:  Bekir Calapkorur; Saban Kelesoglu; Bahadir Sarli; Abdullah Turasan; Huseyin Arinc; Mehmet Gungor Kaya
Journal:  Med Princ Pract       Date:  2014-08-19       Impact factor: 1.927

4.  Brain education-based meditation for patients with hypertension and/or type 2 diabetes: A pilot randomized controlled trial.

Authors:  Seung-Ho Lee; Sun-Mi Hwang; Do-Hyung Kang; Hyun-Jeong Yang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 5.  Type 2 diabetes and psoriasis: links and risks.

Authors:  Jesper Grønlund Holm; Simon Francis Thomsen
Journal:  Psoriasis (Auckl)       Date:  2019-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.